Mayne Pharma Group (AU:MYX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mayne Pharma Group has initiated a patent infringement lawsuit against Sun Pharmaceutical over the alleged infringement of patents related to IMVEXXY, a medication for menopause-related vaginal pain. The lawsuit was filed following Sun Pharma’s application to market a generic version of IMVEXXY, triggering a 30-month stay on FDA approval. Mayne Pharma, a leader in women’s healthcare, vows to defend its intellectual property to support its patients and product franchise.
For further insights into AU:MYX stock, check out TipRanks’ Stock Analysis page.